-
Investigative Ophthalmology & Visual... May 2021Glaucoma remains a poorly understood disease, and identifying biomarkers for early diagnosis is critical to reducing the risk of glaucoma-related visual impairment and...
PURPOSE
Glaucoma remains a poorly understood disease, and identifying biomarkers for early diagnosis is critical to reducing the risk of glaucoma-related visual impairment and blindness. The aim of this review is to provide current metabolic profiles for glaucoma through a summary and analysis of reported metabolites associated with glaucoma.
METHODS
We searched PubMed and Web of Science for metabolomics studies of humans on glaucoma published before November 11, 2020. Studies were included if they assessed the biomarkers of any types of glaucoma and performed mass spectrometry-based or nuclear magnetic resonance-based metabolomics approach. Pathway enrichment analysis and topology analysis were performed to generate a global view of metabolic signatures related to glaucoma using the MetaboAnalyst 3.0.
RESULTS
In total, 18 articles were included in this review, among which 13 studies were focused on open-angle glaucoma (OAG). Seventeen metabolites related to OAG were repeatedly identified, including seven amino acids (arginine, glycine, alanine, lysine, methionine, phenylalanine, tyrosine), two phosphatidylcholine (PC aa C34:2, PC aa C36:4), three complements (acetylcarnitine, propionylcarnitine, butyrylcarnitine), carnitine, glutamine, hypoxanthine, spermine, and spermidine. The pathway analysis implied a major role of amino metabolism in OAG pathophysiology and revealed the metabolic characteristics between different biological samples.
CONCLUSIONS
In this review, we summarize existing metabolomic studies related to glaucoma biomarker identification and point out a series of metabolic disorders in OAG patients, providing information on the molecular mechanism changes in glaucoma. Additional studies are needed to validate existing findings, and future research will need to explore the potential overlap between different biological fluids.
Topics: Biomarkers; Glaucoma, Open-Angle; Humans; Metabolome; Metabolomics
PubMed: 33956051
DOI: 10.1167/iovs.62.6.9 -
Journal of Ethnopharmacology Mar 2020Species of Tragopogon are used in traditional medicine, and consumed as vegetables across the world. In terms of the medicinal uses of Tragopogon, different species have...
ETHNOPHARMACOLOGICAL RELEVANCE
Species of Tragopogon are used in traditional medicine, and consumed as vegetables across the world. In terms of the medicinal uses of Tragopogon, different species have found use in traditional medicine, including uses for wound-healing, treatment of gastrointestinal and hepatic complaints, cancer, kidney and liver dysfunction, inflamed skin and certain cutaneous diseases, as well as constipation, fatigue and anoxia.
AIM OF THE STUDY
The aim of this review is to highlight and critically summarize those species of the genus that have been studied as a source of interesting lead compounds, and their traditional uses and bioactivities.
MATERIALS AND METHODS
A comprehensive and systematic review of literature on traditional uses, phytochemicals and pharmacological properties of the genus Tragopogon was carried out. Information was retrieved from secondary databases such as Scopus, Chemical Abstracts Services (Scifinder), Pubmed, Google Scholar and ScienceDirect, in addition to primary sources including books, PhD and MSc dissertations, and official websites. Species names were validated using "The Plant List" (www.theplantlist.org).
RESULTS
The taxa of the genus Tragopogon are known for their local and traditional uses as medicine for treatment of various diseases, and have been consumed as vegetables and snacks for generations in Eurasia, the Mediterranean, Caucasus, Europe and North America. From the approximately 110 species of Tragopogon, only twelve species have been scientifically evaluated for their bioactivity and/or phytochemical composition. Tragopogon species are a rich source of phytochemical constituents and among those that have been identified are 19 flavonoids, 35 terpenoids, seven bibenzyl derivatives, five benzylphtalides, six stilbenes, nine dihydroisocoumarin derivatives, nine phenylmethane derivatives, three hydroxyphenylacetic acid derivatives, four phenylpropane derivatives, four esters of phenylpropanoic acids, a coumarin derivative, and a spermine derivative. Various extracts of the taxa, in addition to the isolated compounds, demonstrated pharmacological properties such as antitumor, antimicrobial, anti-inflammatory and enzyme inhibitory activities, in addition to hepatoprotective, antihyperlipidaemic and wound-healing properties.
CONCLUSION
This review highlights the traditional uses, phytochemistry and pharmacological properties of the few studied taxa of the genus Tragopogon. Some of the reviewed papers were not of an appropriate methodological standard. For instance, phytochemical profiles were not determined, and the fundamental requirements of the pharmacological properties were not defined such as including appropriate positive and negative controls, and calculating the MIC values. Furthermore, these studies did not provide an in depth evaluation of bioactivity of the extracts and the isolated compounds or in vivo experiments which could indicate therapeutic relevance. From a phytopharmacological point of view, this review recommends more high quality evidence-based research on Tragopogon species for further development of plant-derived remedies and compounds.
Topics: Animals; Biological Assay; Humans; Medicine, Traditional; Phytochemicals; Phytotherapy; Plant Preparations; Tragopogon
PubMed: 31837413
DOI: 10.1016/j.jep.2019.112466 -
Cureus Feb 2024Pancreatic ductal adenocarcinoma (PDAC) is a formidable global health concern with a dire prognosis, highlighting the critical need for early detection strategies. This... (Review)
Review
Pancreatic ductal adenocarcinoma (PDAC) is a formidable global health concern with a dire prognosis, highlighting the critical need for early detection strategies. This systematic review delves into the potential of salivary biomarkers as a non-invasive means for identifying PDAC at its incipient stages. Saliva's proximity to the circulatory system enables the detection of tumor-derived biomolecules, making it an ideal candidate for mass screening. The analysis of three selected studies reveals promising candidates such as Neisseria mucosa, Fusobacterium periodonticum, polyamines, and specific long non-coding RNAs (lncRNAs). Notably, polyamines like spermine show potential in distinguishing PDAC, while lncRNAs HOX transcript antisense RNA (HOTAIR) and plasmacytoma variant translocation 1 (PVT1) exhibit superior sensitivity and specificity compared to traditional serum markers. However, challenges, including small sample sizes and a lack of validation, underscore the need for standardized diagnostic panels and large-scale collaborative studies. Advancements in nanotechnology, machine learning, and ethical considerations are crucial for harnessing the diagnostic potential of saliva. The review emphasizes the imperative for extensive clinical trials to validate salivary biomarkers, ensuring not only diagnostic accuracy but also cost-effectiveness, patient compliance, and long-term benefits in the realm of PDAC screening. Longitudinal studies are recommended to unravel temporal changes in salivary biomarkers, shedding light on disease progression and treatment response.
PubMed: 38550499
DOI: 10.7759/cureus.55003 -
Applied Radiation and Isotopes :... Aug 2023Magnetic nanoparticle-based hyperthermia as a new cancer treatment technology has been applied for some kinds of tumors. To review the different applications and...
Magnetic nanoparticle-based hyperthermia as a new cancer treatment technology has been applied for some kinds of tumors. To review the different applications and effectiveness of this new cancer treatment technique, PubMed, Science Direct, Web of Science, and Google Scholar databases were explored up to November 2022, using the following keywords combined in different ways: "Magnetic Nanoparticles Based Hyperthermia", "Magnetic Nanoparticles" AND "Hyperthermia" AND "Cancer". The obtained results were screened for the title and abstract and the relevant papers were reviewed for further details. Finally, 24 papers were included in the study. These papers have evaluated the application of magnetic nanoparticle-based hyperthermia for treating different cancers including breast, liver, prostate, pancreas, colon, brain, lung, and stem cell. Various nanoparticles including Iron Oxide (FeO, FeO), Dextran Spermine, Iron Chloride, Magnetic nanoparticles conjugated with Liposomes (MCLs), and Variable Molecular Weight Nanoparticles (VMWNPs) were used in different reviewed studies. The results of reviewed studies revealed that the nanoparticle-based hyperthermia technique as a new progressive modality can significantly improve treatment outcomes for some special cancers. Increasing life expectancy by up to 30% using Iron Oxide magnetic nanoparticle-based hyperthermia for pancreatic cancer and increasing tumor ablation by about 33% for other cancers were reported in reviewed articles. However, further studies are required to extend this new treatment technique to other cancers and for providing more accurate information on nanoparticle-based hyperthermia's effectiveness as a complementary technique in cancer treatment.
Topics: Male; Humans; Adult; Magnetite Nanoparticles; Hyperthermia, Induced; Neoplasms; Lung
PubMed: 37257266
DOI: 10.1016/j.apradiso.2023.110873